Dataset Information

Comprehensive proteomic analysis reveals distinct features and diagnostic biomarker panel for early pregnancy loss in histological subtypes

ABSTRACT: Early pregnancy loss (EPL) is a common event in human reproduction and is classified into histological subtypes such as hydropic abortion (HA) and hydatidiform moles, including complete hydatidiform moles (CHMs) and partial hydatidiform moles (PHMs). However, accurate diagnosis and improved patient management remain challenging due to high rates of misdiagnosis and diverse prognostic risks. Therefore, diagnostic biomarkers for EPL are urgently needed. Our study aimed to identify such biomarkers through comprehensive proteomic analysis. Ten CHMs, six PHMs, ten HAs and ten normal control (NC) products of conception were uesed to obtain a proteomic portrait. Parallel reaction monitoring (PRM)-targeted proteomic and regression analyses were employed to validate and select the diagnostic signatures.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Placenta

SUBMITTER: Yating Zhao

LAB HEAD: Jianhua Qian

PROVIDER: PXD055182 | Pride | 2025-05-07

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 39

Publications

Comprehensive Proteomic Analysis Reveals Distinct Features and a Diagnostic Biomarker Panel for Early Pregnancy Loss in Histological Subtypes.

Zhao Yating Y Liang Yingjiqiong Y Cai Luya L Cai Limeng L Huang Bo B Han Peilin P Zhang Xiaofei X Zhang Huifang H Chen Zhen Z Yin Xiangang X Duan Ping P Shou Huafeng H Zhu Xiaoxu X Wang Zhe Z Wan Qihong Q Huang Jinyan J Qian Jianhua J

Molecular & cellular proteomics : MCP 20240924 11

Early pregnancy loss (EPL) is a common event in human reproduction and is classified into histological subtypes such as hydropic abortion (HA) and hydatidiform moles, including complete hydatidiform moles (CHMs) and partial hydatidiform moles (PHMs). However, accurate diagnosis and improved patient management remain challenging due to high rates of misdiagnosis and diverse prognostic risks. Therefore, diagnostic biomarkers for EPL are urgently needed. Our study aimed to identify biomarkers for E ...[more]

PMID: 39321873

Similar Datasets

Project description:Clinical therapeutic human serum albumin (HSA) preparations are manufactured by human plasma from donors and contain some miscellaneous proteins (MPs) except albumin. Multiple studies have demonstrated significant variations in the extent of post-translation modifications, redox states, and antioxidant capacities among HSA preparations from different manufacturers. However, these studies have primarily focused on the albumin molecule itself and have not conducted detailed analysis and comparison of the MPs present in HSA preparations. While there have been a few studies that have reported on the presence of MPs in commercial HSA preparations, research in this area is still relatively scarce. In this study, we employed 4D Label-Free quantitative proteomic technology to conduct identification and analysis of MPs in preparations of human plasma-derived HSA (pHSA) from 6 distinct manufacturers; Additionally, we investigated MPs in recombinant HSA (rHSA) preparations obtained through expression in yeast and rice. There were total 456 different MPs identified in 6 pHSA samples and 96 MPs were detected in all pHSA samples. 52 MPs in the rHSA (expressed in yeast) sample and 152 in the rHSA (expressed in rice) were identified. Haptoglobin, Hemopexin and Transthyretin included the top 8 MPs with the highest relative abundance detected in every pHSA preparations in this study. Bioinformatics (including GO, COG/KOG, KEGG, protein−protein interactions, etc.) analysis showed that the MPs identified in pHSA were basically involved in endopeptidase inhibitor activity, complement and coagulation cascades, biosynthesis of amino acids and cholesterol metabolism. Validation results demonstrated that HP, HPX, TF and TTR could be detected in pHSA but not in rHSA, which were consistent with 4D Label-Free quantitative proteomic results. Compared with previous studies, more trace MPs were detected in pHSA and rHSA preparations by 4D Label-Free quantitative proteomic technology. This could provide a new approach for high-throughput detection of trace MPs in HSA preparations.

			Action	DRS
	ED235LQ_C1_1.pdResult	Other
	ED235LQ_C1_1.raw	Raw
	ED235LQ_C1_10.raw	Raw
	ED235LQ_C1_2.raw	Raw
	ED235LQ_C1_3.raw	Raw